Iodine is no cure for thyroid cancer? The target is the treatment that gives hope to the patient.

The majority of thyroid cancers are pre-pregnantly good, particularly the differentiated thyroid cancer (DTC), and patients are usually able to survive in the long term through surgical excision, radioiodine therapy (I-131) and thyroid hormone inhibition. However, a small proportion of patients develop into iodine-difficult thyroid cancer (RAI-RDTC), in which traditional radioiodine treatments are ineffective and diseases are likely to progress rapidly and decrease significantly later. So, is there any way to treat iodine-difficult thyroid cancer? Today, we are showing you an emerging treatment — target-oriented treatment. What’s iodine-resistant thyroid cancer? In short, the following are difficult iodine thyroid cancers: 1. Radioiodine is not available in the canals: for example, thyroid cancer is de-divalized. 2. Even if the radioiodine is ingestion, the treatment is ineffective: there has been no significant reduction in the disease stove. 3. Diseases continue to progress after sufficient doses of radioactive iodine have been received. For such patients, traditional therapy is often powerless and requires new treatment strategies. The “precision strike” target for target treatment is the hot spot for cancer treatment in recent years. Unlike traditional chemotherapy, the target-oriented treatment works directly with tumour cells by inhibiting access to particular molecules, thus achieving “precision strikes”. In iodine-difficult thyroid cancer, tumour growth and vascular signalling pathways are important targets for target-oriented treatment. These drugs inhibit the growth and transfer of tumours by inhibiting multiple target points, such as the internal vascular growth factor (VEGFR), and disrupting the “blood and nutrients” of tumour cells. How’s the target treatment? Clinical studies have shown that target-to-drugs can significantly prolong a patient ‘ s lack of progress (PFS), and that some patients ‘ stoves have even decreased. However, it should be noted that target-oriented treatment does not fully “cure” cancer and that most patients need long-term medication to control their condition. Another important issue for the side-effect treatment of target-oriented treatment is side-effects. Common side effects include high blood pressure: need for monitoring and control. • Foot and foot syndrome: in the form of hand and foot pain, skin skin. • Wearyness, declining appetite: affecting quality of life. Patients need to work closely with doctors during treatment to deal with adverse reactions in a timely manner. Outlook: Although the multidisciplinary combination of treatment offers new options for people with iodine-difficult thyroid cancer, it is not a single “one-size-fits-all drug”. In practice, multidisciplinary collaboration is often needed, for example, to optimize treatment results by combining surgical, local digestive or new drugs in clinical trials. Iodine incurable thyroid cancer has been prohibitive for patients, but the emergence of targets has given them new hope for treatment. In the course of treatment, patients need not only to understand the mechanisms and potential side effects of drugs, but also to work closely with the medical team to develop the best treatment programmes. If you or your family are facing the challenge of thyroid cancer, you can consult a doctor to see if the target treatment is fit for yourself. I hope the power of science will help more patients win the battle against cancer. Thyroid cancer.